ã¡ãã£ã¢èšäº
èåããã€ãã«ã¡ã¯ãã³ãã®ãªãã¯ãã³æ ªãžã®æãŠã€ã«ã¹å¹æã確èª
ããºãææ°ããŒã¯ 4,860
twitterã³ã¡ã³ã 1,955ä»¶äž 1,001ïœ1,100ä»¶
ç¹äŸæ¿èªããŠã³ããæ²»çè¬ãšããã«äœ¿çšã§ããããã«ããŠã»ããã
éèšåºè©Šéšã§ããã
æåŸ
ããŠãã
æ©ãæ¿èªããŠæ¬²ãã
æ©ãæ¿èªããŠæ¬²ãã
ã¯ã¯ãã³ã§ã¯æäœã¯äœããŠããã®äžæ¹ã§å
ç«åã¯äœäžãããããã§ã¯å€ç°ããã³ããã®æŽèµ°ãæ¢ããäºã¯ã§ãããã«ãªããã€ãã«ã¡ã¯ãã³ã®æãŠã€ã«ã¹å¹æã«æåŸ
ãããã
ããã©ããªãã ãããªïŒçŽ äººçã«ã¯å€æåºæ¥ãªãã®ã§å°éå®¶ã®è©±ãä¿¡ãããããã³ã¡ã³ãã¯ããã£ããŒïŒãçãªã®ãå€ããã ãã©ã
èåããã«æè¬âš
éœæ§ãå€ææ¬¡ç¬¬æçšåºæ¥ãããããã³ãããæããªãïŒ
éœæ§ãå€ææ¬¡ç¬¬æçšåºæ¥ãããããã³ãããæããªãïŒ
èåãã€ãœãžã³åæãæ¶è²»è
åºããæããã¯ã¬ããªã³ãå
šãç¬ããªããçŽ
è¶ãå
¥ããããŠã€ã«ã¹ã倱掻ããŸããïŒïŒãã¬ãã«ã®ãã¬ã¹ãªãªãŒã¹ãåºãæããã£ããæ©ãã€ãã«ã¡ã¯ãã³æ²»éšã®äžéå ±åãåºããšããææ³ãããªãâºïž
åæå§ãŸã£ãŠããªã
ã¡ãã£ãšã¢ã¬ãªäººãã¡ãæšããŠããã®ã§ã€ãã¢ãã«ãªã£ãŠããŸãããæ¬åœã«å¹ãã®ãã©ããã¯å¥åé¡ã
泚ç®ã¯ããŠããŸãã
泚ç®ã¯ããŠããŸãã
ãã£ãšã(ï¿£âœï¿£)
æ¿èªãŸã§ãŸã ãããããããªïŒïœïœïŒ
æ¿èªãŸã§ãŸã ãããããããªïŒïœïœïŒ
ããç¡ãã£ãããšã«ã¯åºæ¥ãªãããïŒ
æåããå¹ããã ããã³ããã¯äººçœã
ã¿ããªãèªåã®é ã§èãããšäºãæãåºããïŒ
æ¥æ¬äººãå¿ããŠããŸã£ãããšâŠ
æåããå¹ããã ããã³ããã¯äººçœã
ã¿ããªãèªåã®é ã§èãããšäºãæãåºããïŒ
æ¥æ¬äººãå¿ããŠããŸã£ãããšâŠ
éèšåºã§ïŒïŒ
MSDã广ãªãã£ãŠå ¬åŒçºè¡šããŠãã®ã«ïŒïŒ
MSDã广ãªãã£ãŠå ¬åŒçºè¡šããŠãã®ã«ïŒïŒ
ãã¯ã¯ãã³ããæ²»çè¬ãžãã«ãªããã©ããã
èšã£ããã¯ã¯ãã³ã¯æ°åéããŠæªçéãããããã§ããã
éé³ã¯åãä»ããªãã
èšã£ããã¯ã¯ãã³ã¯æ°åéããŠæªçéãããããã§ããã
éé³ã¯åãä»ããªãã
åŠã«åŠå®çãªäººãæ©éã¡ãã»ãèŠãããŸãããðåšåº«ãæããªãã£...ãããè¬ãæ®åãããäœãéœåãæªãããšã§ããããã§ããããã
ã€ãã«ã¡ã¯ãã³ã¯å
¥æããŠããã©æçšããŠãªããåã¯ã¯ãã³æŽŸãæäžäž»ã®ããã«åŽãã察象ãšãæã£ãŠãªãããšã«ããéèšåºå®éšãªã®ã§ã人ãžã®æ²»éšã§å¹æãå®èšŒããããæ€èšããªã
ãŸã èšåºãã£ãŠãªãã®ã
詊éšç®¡å
ã®è©±ãã
ããããã€ãã«ã¡ã¯ãã³å士æ¯èŒããŠãæå³ç¡ãã®ã§ã¯ã
å®ã¯ãæ¿ãããå¡©æ°Žãšã©ã£ãããªããããªã?
ããããã€ãã«ã¡ã¯ãã³å士æ¯èŒããŠãæå³ç¡ãã®ã§ã¯ã
å®ã¯ãæ¿ãããå¡©æ°Žãšã©ã£ãããªããããªã?
(-Ï-;)ãŠãŒã³
Japan's Kowa says ivermectin effective against Omicron in phase III trial
Japan's Kowa says ivermectin effective against Omicron in phase III trial
ã¡ã«ã¯ç€ŸãäŸçµŠããªããªãèåããã«äŸçµŠããŠãããããã
âŠ
âŠ
å¹ããªããšãäžéšã®é£äžãéšãã§ããã广ãããããªããã
ãŠããããåãã仿¥çºè¡šããããã£ã¡âã°ããæ³šç®ãããŠããã®äžæè°ã ãŒã
ãéèšåºè©Šéšã§ãªãã¯ãã³æ ªã«ãæãŠã€ã«ã¹å¹æããšãããªãã第äžäžå ±ããã¬ã¹ãªãªãŒã¹ã§åãããšãããå ·äœçã«èšã£ãŠããã®ã§ã¯(ç§ã®çè§£ã§ã¯)ã
åºå ±æŠç¥ã®éããªãã ãããã
ãéèšåºè©Šéšã§ãªãã¯ãã³æ ªã«ãæãŠã€ã«ã¹å¹æããšãããªãã第äžäžå ±ããã¬ã¹ãªãªãŒã¹ã§åãããšãããå ·äœçã«èšã£ãŠããã®ã§ã¯(ç§ã®çè§£ã§ã¯)ã
åºå ±æŠç¥ã®éããªãã ãããã
ããããã€ãã«ã¡ã¯ãã³æ¥ããïŒ
æšå¹Ž9æäžæ¬ãã飲ãã§ããŸãã
æ²»çè¬ã«åžæãã
ãªãã¯ãã³æ ªã«å¯ŸããŠãããã ã£ãŠããæ©ã䜿ãããïŒïŒmRNAã¯ã¯ãã³åæ§ã«ãâŠâŠðãã£ãŠãäºãã°ãã°ãããã
ïŒ20:24ïŒ
ïŒ20:24ïŒ
誰ãããéã®éå²ãã«ãªããªããšçµå±æœ°ãããããããªãïŒ
ãããã£ãæ¢åè¬ã«ããæ°åãŠã€ã«ã¹ãžã®å¹æè©Šéšãã
åœãå šé¢çã«ããã¯ã¢ããããŠããããšæãã
æ°è¬ããå®ãã»å¯äœçšã ããçšåºŠã¯å€æããŠããã®ã ããã
åœãå šé¢çã«ããã¯ã¢ããããŠããããšæãã
æ°è¬ããå®ãã»å¯äœçšã ããçšåºŠã¯å€æããŠããã®ã ããã
ð§ã€ãã«åºãïŒçŽ æŽããããïŒããã§ãšãããããŸããïžððððŸðâš
åå€å±ã®çŽ¡çžŸå瀟ããããªããªãã«ãŠããŒã¯ãªã»ã³ã¹ããæã¡ã®ããã§è¶£æ·±ãã§ããªãð¥º
åå¿é²ãã€ãã«ã¡ã¯ãã³ã«é¢ããŠã
æ¥ä»ééã£ãŠãã®ã§å ã®ãã€æ¶ããŠåæçš¿ïœœïŸïœ¿w
âå±±éœæ°è 2022/01/22ã®èšäº
æå¯çè«è¬ ã³ããæ²»ç广ã«èªä¿¡
âãã€ã¿ãŒ 2022/01/31ã®èšäº
æ¥ä»ééã£ãŠãã®ã§å ã®ãã€æ¶ããŠåæçš¿ïœœïŸïœ¿w
âå±±éœæ°è 2022/01/22ã®èšäº
æå¯çè«è¬ ã³ããæ²»ç广ã«èªä¿¡
âãã€ã¿ãŒ 2022/01/31ã®èšäº
ããæå ±ïŒ
ããããKãããåç· åœ¹ã§ããããããªãã«ãªããšã¯ãããªãã£ãã ããã«ããªããå°ã«èœã¡ããªã
ææå·®åºãã®ãïŒïŒè©³ããããŒã¿èŠããã§ããã
éèšåºè©Šéšããããªå ±ãæ¹ããã®ãããã
ãã£ãœã©åºåè²»æã£ãŠããã ãããª
ä»ã®å€ç°æ ªã«å¹æãªããšèšãããããšããªãã£ãããšã®ããã«æžããŠãããŸãã§ãã¹ãŽã
ãã£ãœã©åºåè²»æã£ãŠããã ãããª
ä»ã®å€ç°æ ªã«å¹æãªããšèšãããããšããªãã£ãããšã®ããã«æžããŠãããŸãã§ãã¹ãŽã
éèšåºè©Šéšã ãšãªãã
æ¢åã®è¬ã§äœãšãããããšããªãã®ã¯ããã¯ã婿š©ã絡ãã§ãããããªã®ãã
ãŸã念ã®ããã«ã€ãã«ã¡ã¯ãã³ã¯å°ãæã«ãããŠããã®ã§ãããææãããå»è ã®è©±ã¯ç¡èŠãããŠäœ¿ã£ãŠã¿ããã
ãŸã念ã®ããã«ã€ãã«ã¡ã¯ãã³ã¯å°ãæã«ãããŠããã®ã§ãããææãããå»è ã®è©±ã¯ç¡èŠãããŠäœ¿ã£ãŠã¿ããã
ãåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒãã»ã»ã»ïœ±ïœ€ïŸïœ²ã
ãã€ã¿ãŒãå ±ããŠ
ã©ããã£ãŠã€ãã«ã¡ã¯ãã³ã¯
å¹ããªãè¬ã ã£ãŠãã£ã³ããŒã³
ãããã®ã§ããããïŒ
ã²ã€ãããé 匵ã£ãŠãïœ
ã©ããã£ãŠã€ãã«ã¡ã¯ãã³ã¯
å¹ããªãè¬ã ã£ãŠãã£ã³ããŒã³
ãããã®ã§ããããïŒ
ã²ã€ãããé 匵ã£ãŠãïœ
æ®æ¥ããåž°ã£ãŠããŠTV芳ãŠã¿ãã°ã¯ã¯ãã³ã®è©±é¡ã§ããïŒ
ãããæ¢ããŠ
ã®è©±é¡ã«ããŸããããã
ãããæ¢ããŠ
ã®è©±é¡ã«ããŸããããã
ããç¡ãã£ãããšã«ã¯åºæ¥ãªãããïŒ
æåããå¹ããã ããã³ããã¯äººçœã
ã¿ããªãèªåã®é ã§èãããšäºãæãåºããïŒ
æ¥æ¬äººãå¿ããŠããŸã£ãããšâŠ
æåããå¹ããã ããã³ããã¯äººçœã
ã¿ããªãèªåã®é ã§èãããšäºãæãåºããïŒ
æ¥æ¬äººãå¿ããŠããŸã£ãããšâŠ
ããã«ã¡ãã£ã¢ã§ç¡è²¬ä»»ãªããšãèšãæŸã¡æšæž¬ã»æ¶æž¬ã§äººãäžå®ã«é¥ããè
ã©ãã®æç°åŒæ°Žã ã£ããã£ãŠè©±ã
ããïŒã¡ãããšèªããïŒ
ãã®ãããéèšåºè©Šéšã§ãããããå
容ã¯åãããªãã§ããã©åãããããèšãã°ã¯ã¬ããªã³ãšåã詊éšç®¡å
ã®è©±ã§ã
åäººèŒžå ¥ãããè©æ¬ºã«éããªãããã«ããŠäžãããè©æ¬ºåž«ã¯ãã®ã¿ã€ãã³ã°ãèŠéããŸãããã
åäººèŒžå ¥ãããè©æ¬ºã«éããªãããã«ããŠäžãããè©æ¬ºåž«ã¯ãã®ã¿ã€ãã³ã°ãèŠéããŸãããã
å»å¹Žã®6æã ãâŒïž åœæ°ã銬鹿ã«ãããªâŒïž
ã³ãããæ çæããã®è¶çªãªäºãè¯ããããâŒïžð¡ð¢
ã³ãããæ çæããã®è¶çªãªäºãè¯ããããâŒïžð¡ð¢
éèšåºè©Šéšã®çµæãèšåºè©Šéšã®çµæã ãšèª€èªãããæªè³ªãªèšäºã
å®éã«æè¬ãæ²»çã«çµæãåºããŠã鿥å»ã®è©±ãããã¬ãã«åºãŠããå»åž«éã¯äžããç®ç·ã§å¹æããã¯ãããªããšå
šåŠå®ããŠãŸããããã
ïŒåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒ
éèšåºè©Šéš
é èš åº è©Š éš
é èš åº è©Š éš
éèšåºè©Šéš
é èš åº è©Š éš
é èš åº è©Š éš
ã³ãããæŠæŒ¢ã§æµè¡ãã ããé ã«ã¯ç¥ã£ãŠãããšãèªãããå§ãã
æ¿èª(èªå¯ïŒ)ãããããªïŒ
æ¬åœã«å®çšæ¡ä»¶äžã§å¹æããããšããªãæå ±ã§ããããã©ããªã®ãã
ããã£ãŠè¯ãåãããªãããããããªã®ä¿¡ããã®ã¢ããããèšã人ãããããäžå¿å»å¹Žè²·ã£ããã ããŸã 飲ãã§ãªãããå®ã代ããã«äžå¿è²·ã£ãŠã¿ãã
ãã®è¬ãæå¹ãªã®ã§ã¯ãªãããšãããéååããææãããŠãããšæããŸãã
ããããåãã®ç®ãåœæ°ããå¥ããããåã«ãå
¬è¡šãããã©ãã§ããïŒãåœæ°ç掻ãå¥åº·ãã婿š©åªå
ãªãã ãªãšå®æãããããæ°ãããŸãã
ãããäºå®ãªãããªãæå ±âš
ã³ããåœåãã€ãã«ã¡ã¯ãã³ã¯å¹ããªãã£ãŠèšã£ãŠãå»è ãªããªãã
ã³ããåœåãã€ãã«ã¡ã¯ãã³ã¯å¹ããªãã£ãŠèšã£ãŠãå»è ãªããªãã
ãªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šããã
ããã€ãã«ã¡ã¯ãã³ã§ãããã軜çã«ã¯ãã³ããèŠãã®é¢šéªè¬ã飲ãã°ãããðã¯çµäºã§âãããªãã
ããã€ãã«ã¡ã¯ãã³ã§ãããã軜çã«ã¯ãã³ããèŠãã®é¢šéªè¬ã飲ãã°ãããðã¯çµäºã§âãããªãã
æ¡ã®å®ã³ã¡ã³ããã²ã©ãããã¿ã€ãã«ãå°ãã¯èããŠãã (ŽÏ`)
ãããŒã«83L飲ãã°çèèåæå¶ã ã¿ããã«ãéèšåºè©Šéšãªããããã§ãèšããã
ãããŒã«83L飲ãã°çèèåæå¶ã ã¿ããã«ãéèšåºè©Šéšãªããããã§ãèšããã
第ïŒçžèšåºè©Šéšãè¡ã£ãŠãããã€ãã«ã¡ã¯ãã³ãã«ã€ããŠãåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒããããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡š
ã¡ãŒã«ãŒã®çºè¡šãšè«æã¯ã©ã£ã¡ãä¿¡çšã§ãããïŒèŠåºãã§ããã®äœçœ®ãéãã®ãè峿·±ã
èå ã€ãã«ã¡ã¯ãã³ã®ããªãã¯ãã³æ ªããžã®æãŠã€ã«ã¹å¹æã確èª
èå ã€ãã«ã¡ã¯ãã³ã®ããªãã¯ãã³æ ªããžã®æãŠã€ã«ã¹å¹æã確èª
ã€ãã«ã¡ã¯ãã³åã³ïŒ
ã§ããæ¿èªãããªãããšã«ã¯éç£ãã§ããªããå²ãããªãããââãåããªãããŸã ãŸã å
ããããé¢ä¿è
ã®çæ§ã«å¯ŸããŠãã©ã®ãããªå¿æŽãã§ããã ãããã
èåã¯31æ¥ãæ°åã³ãããŠã€ã«ã¹ææçã®æ²»çè¬ãšããŠç¬¬3çžèšåºè©Šéšãè¡ã£ãŠãã ã«ã€ããŠãåé倧åŠãšã®å
±åç ç©¶(éèšåºè©Šéš)ããããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šã
ã€ãã«ã¡ã¯ãã³ãé°è¬è«æ±ãããŠã奎ãã¯äœ¿ããªãã§ã»ããã
ã ã£ãŠåœŒãã«ã¯ç¥ã¯ã¯ãã³ãããããå¿ èŠãªãã§ãã
ã¯ã¯ãã³ã¯ææãé²ããšãããæµããŠãã®ã¯ã¯ã¯ãã³ä¿¡è ã®ã»ã
ã ã£ãŠåœŒãã«ã¯ç¥ã¯ã¯ãã³ãããããå¿ èŠãªãã§ãã
ã¯ã¯ãã³ã¯ææãé²ããšãããæµããŠãã®ã¯ã¯ã¯ãã³ä¿¡è ã®ã»ã
ãåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒãããã¯ãã¯ããä»åºŠã¯èåã⊠â
ãããã€ãã«ã¡ã¯ãã³ã
ãã³ã¶ãšãŒã¹ãšããããã³ãããã ãã¶å¹ããæ°ããããããã¯ãããããŠäžçåã®é¢šéªè¬ã§ã¯ïŒ
ãã³ã¶ãšãŒã¹ãšããããã³ãããã ãã¶å¹ããæ°ããããããã¯ãããããŠäžçåã®é¢šéªè¬ã§ã¯ïŒ
ããèªãã§ãã广ã確èªãããã®ã¯ãéãèšåºè©Šéšã®æ¹ã§ã第äžçžèšåºè©Šéšã®ã»ãã«ã¯èšåããŠãªãã§ãããèŠããã«ãã³ããã«å¯ŸããŠã¯å¹æãããã蚌æãããŠããªãïŒå¹æããªããšã蚌æãããŠããªãïŒããšãããã¥ãŒã¹ã ãããããªèšäºãèš±ãããã®ïŒ
ããŒããæ£ã
å©ããŠãã人ã¯äœã ã£ããã ããã
ã?
ãŸã ã€ãã«ã¡ã¯ãã³ã¯æ€èšãããŠãã®??
广ãå šããªããšã¯èšããªãããæ¢åã®è¬ãè¶ ãããšã¯ãäžèŸã«ãæããªããâŠ
ãŸã ã€ãã«ã¡ã¯ãã³ã¯æ€èšãããŠãã®??
广ãå šããªããšã¯èšããªãããæ¢åã®è¬ãè¶ ãããšã¯ãäžèŸã«ãæããªããâŠ
äžç¬çŠã£ãâŠ
ããã«ã¿æ ªçã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªã
ãªãã ããä»ã®æ ªãšåã广ãïŒã广ãªãïŒããâºïž
æ¥æ¬èªã®èšäºããèªããªãã€ãã«ã¡ã¯ãã³æŽŸã鬌ã®éŠãåã£ãããã«çåããå§¿ãæ³åã§ããâŠâºïž
ããã«ã¿æ ªçã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªã
ãªãã ããä»ã®æ ªãšåã广ãïŒã广ãªãïŒããâºïž
æ¥æ¬èªã®èšäºããèªããªãã€ãã«ã¡ã¯ãã³æŽŸã鬌ã®éŠãåã£ãããã«çåããå§¿ãæ³åã§ããâŠâºïž
ã³ã¡ã³ãæ¬ãå°çã§è
ã£ãŠèšããããä¿¡ããŠé£²ãã 人éã§ãéçåããäºå®ãã¯ã¯ãã³åæ§ å¹ããå
«åŠãå¹ãã¬ãå
«åŠã
çã£èµ€ãªè²ã®æ°æã¡æªãæ¯ç©ãç·æ¥æ¿èªã§ãããªãã€ãã«ã®æ¹ããã»ã©å®å¿ã ãã
æµ·å€å®çžŸãç·æ¥æ¿èªã®æ ¹æ ãªãæ¿èªã§ããã ãã
ããããå®éã«èšºçã«äœ¿ã£ãããŒã¿ã沢山ãããšèšãã®ã«
æµ·å€å®çžŸãç·æ¥æ¿èªã®æ ¹æ ãªãæ¿èªã§ããã ãã
ããããå®éã«èšºçã«äœ¿ã£ãããŒã¿ã沢山ãããšèšãã®ã«
ã¶ã»ã€ãã³ã¡ãªã€ãã³ã¡ã䞊ãã§ãããªãŒã
èåã¯31æ¥ãæ°åã³ããã®æ²»çè¬ãšããŠç¬¬3çžèšåºè©Šéšãè¡ã£ãŠãããã€ãã«ã¡ã¯ãã³ãã«ã€ããŠããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šã
ïŸââââ(ïŸâïŸ)ââââ!!
åéã®çæ§ãã£ãšã§ãã
æ¥æ¬ãäžçãæãç¬¬äžæ©
åéã®çæ§ãã£ãšã§ãã
æ¥æ¬ãäžçãæãç¬¬äžæ©
仿Žãããã ã
ãã£ãšæ¥ãããã£ãŠæãã
èåãšåé倧åŠã®åªåã«å ±ããŠå·®ãäžããŠãã ããããããæ©ã«5é¡ã«å€æŽããŠäžããããã®ãã£ã³ã¹ãéãããä¿¡çšã¬ã¿èœã¡ã§ããåç§äŒãã圹ç®åŸ¡å
ã§ããåŠæ¹å®çžŸã®ããå»è
ãæ°ããªã¢ããã€ã¶ãŒã«ãã¹ãã§ãã
ãã¯ãæåŸ
åºæ¥ãã®ã¯ã€ãã«ã¡ã¯ãã³ãªã®ã
ãåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒããããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šã
ä»ã§ããïŒã³ãŒã¯ãã ç©æ¥µçã«æ¿æ²»çã«åããŠäžããïŒ
ã€ãã«ã¡ã¯ãã³ã«åŠå®çã ã£ã人ãã¡ã®ãæèŠããèãããããã
çµå±ãæ¢åè¬ã§ã¯å²ãããªããããå©ããŠãæ°è¬ã§éå²ãããããããã ãã®ã³ããéšåã ã£ããã ãã»ã»ã»
çµå±ãæ¢åè¬ã§ã¯å²ãããªããããå©ããŠãæ°è¬ã§éå²ãããããããã ãã®ã³ããéšåã ã£ããã ãã»ã»ã»
æå ±:
1/31ä»ã®
ã€ãã«ã¡ã¯ãã³ã¯ç¬¬ïŒå±€è©Šéšäžããã«ã¿æ ªããªãã¯ãã³æ ªãªã©å€ç°æ ªã«å¯ŸããŠã广ãèªãããããšçºè¡šãããŸãããïŒãã€ã¿ãŒéä¿¡ïŒ
1/31ä»ã®
ã€ãã«ã¡ã¯ãã³ã¯ç¬¬ïŒå±€è©Šéšäžããã«ã¿æ ªããªãã¯ãã³æ ªãªã©å€ç°æ ªã«å¯ŸããŠã广ãèªãããããšçºè¡šãããŸãããïŒãã€ã¿ãŒéä¿¡ïŒ
ããå æžãéèšåºè©Šéšããã£ãŠã广ã確èªããšããã®ã¯ãããããã¹ãŽãã¯ãããããã¹ãªãŒããèªãèŠåºãã§ã€ãã«ã¡ã¯ãã³ä¿¡è
ãç
œã£ãŠãèªèŠãæãŠããããããã«ãã
ã³ãŒã¯ããé 匵ããŸããððð
ãšãããã第äžå ±ãšããã³ãã§ For the time being ,it's the first report. It is an article that a company recognized the effect of ivermectin. However, the company was dismissed for initiating a clinical trial of ivermectin.
ãããŒïŒã€ããŒãã¥ãŒã¹ã§åãäžããŠããâŠïŒ
ãéãèšåºè©Šéšã ãããªããRCTã®çµæãåºãªããšãŸã ããããã广ãåŠå®ããæ°ã¯ãªããã©ãèªåãä¿¡ããããã¥ãŒã¹ãã詳现ãçè§£ããã«è³è³ãã人ãå€ãã®ã¯ãåŠäœãªããããã
ããã¯ã¯ã¯ãã³æ¥çš®è
ã«ãéæ¥çš®è
ã«ãæå ±ã ã
ãããŠç¡äºè²©å£²ãŸã§èŸ¿ãçãããã©ããã
ãããäžã«åºåããšãŸããŸãã¯ã¯ãã³æ¥çš®ã¯æžããã¡ã«ã¯ããããã補é ããŠãã€ãããæãåŒããã®ã¯ãã¢ã«ããã©ãã«ã§å€§å²ãããããã ããéªéãããããããã
ãããäžã«åºåããšãŸããŸãã¯ã¯ãã³æ¥çš®ã¯æžããã¡ã«ã¯ããããã補é ããŠãã€ãããæãåŒããã®ã¯ãã¢ã«ããã©ãã«ã§å€§å²ãããããã ããéªéãããããããã
ããããã€ã¿ãŒã§åºãã
ããã§ã³ããçµããããã
ããã§ã³ããçµããããã
äžå®¶ã«äžç®±ãåããŸããããð¯ð
åå¿é²ãã€ãã«ã¡ã¯ãã³ã«é¢ããŠã
âå±±éœæ°è 2021/01/22ã®èšäº
æå¯çè«è¬ ã³ããæ²»ç广ã«èªä¿¡
âãã€ã¿ãŒ 2021/01/31ã®èšäº
âå±±éœæ°è 2021/01/22ã®èšäº
æå¯çè«è¬ ã³ããæ²»ç广ã«èªä¿¡
âãã€ã¿ãŒ 2021/01/31ã®èšäº
æ¿åºãããã¯ã¢ããããŠãæ©ã䜿ããããã«ããŠã»ããã
èåãå¯çè«ææçæ²»çè¬ãã€ãã«ã¡ã¯ãã³ãã®ãªãã¯ãã³æ ªãžã®æãŠã€ã«ã¹å¹æã確èªãããšçºè¡š
0ãšåããªãããã¯ã€ãŸã0ãªãã§ããð¥º
éèšåºè©Šéšã¯èw
éèšåºè©ŠéšãããâŠ
ããäžåèšããã©
é èš åº è©Š éš ãããâŠ
ããäžåèšããã©
é èš åº è©Š éš ãããâŠ
ãã£ãïŒïŒïŒ
âåé倧åŠãšã®å
±åç ç©¶ïŒéèšåºè©ŠéšïŒããããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šããâ
åŸ ã¡æãã§ããæå ±ïŒ
åŸ ã¡æãã§ããæå ±ïŒ
ã»éèšåºè©Šéšã§ã®çµæã§ãã
ã»èšåºè©Šéšã§åŠå®çãªçµæãç©ã¿äžãã£ãŠãä»ã®æ ªã«å¯ŸããŠãšåçã®çµæã§ãã
ã®ã«ã©ããªæéãããã¯æªèŸ£ãªè³ã¿ãæã£ãŠãããããªã¿ã€ãã«ãæžãããã§ããã
ã»èšåºè©Šéšã§åŠå®çãªçµæãç©ã¿äžãã£ãŠãä»ã®æ ªã«å¯ŸããŠãšåçã®çµæã§ãã
ã®ã«ã©ããªæéãããã¯æªèŸ£ãªè³ã¿ãæã£ãŠãããããªã¿ã€ãã«ãæžãããã§ããã